Heat Biologics Completes Enrollment in Phase 2 Non-Small Cell Lung Cancer Trial

Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure

2019 Annual Meeting of Stockholders

Jul 23, 2019 • 10:00am EDT